Gyre Therapeutics Past Earnings Performance
Past criteria checks 0/6
Gyre Therapeutics's earnings have been declining at an average annual rate of -1976%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 9% per year.
Key information
-1,976.0%
Earnings growth rate
-1,559.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -9.0% |
| Return on equity | -84.9% |
| Net Margin | -84.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Gyre Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 105 | -89 | 78 | 13 |
| 30 Jun 24 | 112 | -86 | 75 | 13 |
| 31 Mar 24 | 116 | -88 | 77 | 13 |
| 31 Dec 23 | 113 | -93 | 76 | 14 |
| 30 Sep 23 | 115 | 5 | 72 | 15 |
| 30 Jun 23 | 113 | -2 | 80 | 19 |
| 31 Mar 23 | 104 | 0 | 73 | 17 |
| 31 Dec 22 | 102 | 2 | 72 | 17 |
Quality Earnings: GYRE is currently unprofitable.
Growing Profit Margin: GYRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if GYRE's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare GYRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GYRE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: GYRE has a negative Return on Equity (-84.94%), as it is currently unprofitable.